Price
No data yet.
Social Signal Score
Analyst Ratings
9 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Ronald H. W. Cooper
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 82
- Beta
- -0.28
- Country
- CA
- Piotroski score
- 0 / 9 (Weak)
- Altman Z-score
- -1.39
Financials
Net Income
$32.50MEBITDA
$-33.84MFree Cash Flow
$-18.95MEPS (diluted)
$0.47Shares Outstanding (diluted)
69.73M+341.0%Operating Expenses
$34.01MCash & Debt
$266.32MDividend per Share
$0.13Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-117.30M | $-2.29 |
| 2024 | $0.00 | $-55.14M | $-1.46 |
| 2023 | $0.00 | $-99.92M | $-4.24 |
| 2022 | $0.00 | $-24.46M | $-1.84 |
| 2021 | $0.00 | $-23.44M | $-0.01 |
| 2020 | $0.00 | $-15.07M | $-0.95 |
Valuation
ENGNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+0.00%Social Signal Score
Mentions (5)
- Newsseekingalpha.com·21d ago·Positive
enGene Therapeutics Inc. (ENGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript enGene Therapeutics Inc. (ENGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·25d ago·Neutral
… To Bring Their Asset To The Market enGene Therapeutics remains deeply undervalued, trading below its $3.97/share cash position despite pipeline and execution risks. ENGN's lead asset, detalimogene voraplasmid, faces FDA approval risk due to weak 12-month durability, but management is pursuing a surfactant cohort to address efficacy. Cost-saving measures, including a 50% workforce reduction, extend ENGN's cash runway into 2029, supporting operations through pivotal BLA milestones.
View source ↗ - Newsbusinesswire.com·28d ago·Neutral
enGene Reports Third Quarter 2026 Financial Results and Provides Business Update BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the third quarter ended July 31, 2026, and provided clinical and corporate updates. “As we move through the second half of 2026, our focus is on maturing regulatory endpoints data from LEGEND's pivotal cohort and our p…
View source ↗ - Newsmarketbeat.com·53d ago·Neutral
enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market enGene NASDAQ: ENGN outlined its view of the high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer, or NMIBC, market, citing market research that it believes supports a larger addressable patient population and greater use of treatment sequencing before radical cystectomy.
View source ↗ - Newsseekingalpha.com·55d ago·Positive
enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder Cancer Transcript enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder Cancer Transcript
View source ↗
Earnings
Mon, Dec 28(in 3 months)
Consensus estimate $-0.46 per share
Typical surprise -10.2% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Sep 8$-0.47 vs $-0.43miss
- Mon, Jun 15$-0.43 vs $-0.48beat
- Mon, Mar 9$-0.44 vs $-0.55beat
- Mon, Dec 22$-0.73 vs $-0.57miss
- Thu, Sep 11$-0.57 vs $-0.50miss
- Thu, Jun 12$-0.51 vs $-0.50miss
Estimates and results for ENGN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ENGN officers and directors.
- Bought
- $8.1m
- Sold
- $788k
16 trades
3 trades
- Grossman Williambought
- Forbion Growth Opportunities Fund I Cooperatief U.a.bought
- Forbion Growth Opportunities Fund I Cooperatief U.a.bought
- Forbion Growth Opportunities Fund I Cooperatief U.a.bought
- Forbion Growth Opportunities Fund I Cooperatief U.a.bought
- Forbion Growth Opportunities Fund I Cooperatief U.a.bought
- Forbion Growth Opportunities Fund I Cooperatief U.a.bought
- Forbion Growth Opportunities Fund I Cooperatief U.a.bought
81 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ENGN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.